<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42058">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558829</url>
  </required_header>
  <id_info>
    <org_study_id>AEZS-130-052</org_study_id>
    <secondary_id>2015-002337-22</secondary_id>
    <nct_id>NCT02558829</nct_id>
  </id_info>
  <brief_title>Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency</brief_title>
  <official_title>Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Macimorelin-GHST (growth hormone stimulation test) will be compared with the ITT
      (insulin tolerance test) in an open-label, randomized, 2-way crossover Trial. The trial will
      include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of
      healthy control subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial subjects will be assigned to groups of descending likelihood of having AGHD:

      Group A, B, C: High, intermediate, and low likelihood of GHD, respectively; Group D: Healthy
      control subjects matching Group A subjects .

      The sequential order of the GHSTs for suspected AGHD subjects (Group A-C) will be determined
      by stratified randomization; healthy control subjects (Group D) will be tested in the same
      sequence as the matched Group A subjects.

      Serum concentrations of GH will be measured at pre-defined time points before and after GHST
      with macimorelin or insulin. A peak GH value below the GHST-specific cut-off value will be
      considered 'test positive'. The ITT will be considered as comparator (non-reference
      standard) to assess positive and negative agreement of both GHSTs, based on the predefined
      cut-off values.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">November 29, 2016</completion_date>
  <primary_completion_date type="Actual">November 29, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
    <masking_description>This was an open label trial. No masking with regard to the Growth Hormone Stimulation Tests (GHSTs) performed was done. However, Data Review Committee/Sponsor/Project Management was masked towards the Growth Hormone (GH) values as results fo both tests. GH values were provided to the investigator only after both GHSTs had been performed, to avoid bias.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent positive/ percent negative agreement of Macimorelin-GHST with ITT</measure>
    <time_frame>28 days</time_frame>
    <description>Percent positive agreement (upper limit for crossover interval between both GHSTs); percent negative agreement of Macimorelin-GHST with ITT. Percent positive and negative agreement are defined as co-primary outcome measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent overall agreement of Macimorelin-GHST with ITT</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 28 days</time_frame>
    <description>AEs during GHST and follow-up until second GHST or end-of-trial visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>60 minutes</time_frame>
    <description>Pre/post dose comparison of ECGs for both GHSTs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Estimated sensitivity of Macimorelin-GHST</measure>
    <time_frame>90 minutes</time_frame>
    <description>Exploratory evaluation of sensitivity and specificity based on GH Peak Levels in Group A and Group D subjects</description>
  </other_outcome>
  <other_outcome>
    <measure>Estimated specificity of Macimorelin-GHST</measure>
    <time_frame>90 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Estimated sensitivity of ITT</measure>
    <time_frame>120 minutes</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Estimated specificity of ITT</measure>
    <time_frame>120 minutes</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Growth Hormone Deficiency With Pituitary Anomalies</condition>
  <arm_group>
    <arm_group_label>GHST Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st Macimorelin-GHST, 2nd Insulin Tolerance Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GHST Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st Insulin Tolerance Test, 2nd Macimorelin-GHST</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macimorelin</intervention_name>
    <description>macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose</description>
    <arm_group_label>GHST Sequence A</arm_group_label>
    <arm_group_label>GHST Sequence B</arm_group_label>
    <other_name>Macimorelin-GHST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose</description>
    <arm_group_label>GHST Sequence A</arm_group_label>
    <arm_group_label>GHST Sequence B</arm_group_label>
    <other_name>Insulin Tolerance Test (ITT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected growth hormone deficiency (GHD), based on either of the following:

               -  structural hypothalamic or pituitary disease, or

               -  surgery or irradiation in these areas, or

               -  head trauma as an adult, or

               -  evidence of other pituitary hormone deficiencies, or

               -  idiopathic childhood onset GHD (without known hypothalamic or pituitary lesion
                  or injury).

          -  Healthy* control subjects, matching a 'high likelihood GHD' subjects

        Exclusion Criteria:

          -  GH therapy within 1 month prior to anticipated first GHST within this trial (within 3
             months in case of long-acting GH formulation).

          -  GHST within 7 days prior to the anticipated first test day within the trial.

          -  Subjects that are not euthyroid, or subjects who had a change in thyroid therapy
             within 8 weeks prior to anticipated first test day within the trial.

          -  Untreated hypogonadism or not on a stable substitution treatment within 30 days prior
             to anticipated first test day within the trial.

          -  Treatment with drugs directly affecting the pituitary secretion of somatotropin (e.g.
             somatostatin analogues, clonidine, levodopa, and dopamine agonists) or provoking the
             release of somatostatin; antimuscarinic agents (atropine).

          -  Concomitant use of a CYP3A4 inducer (e.g., carbamazepine, phenobarbital, phenytoin,
             pioglitazone, rifabutin, rifampin, St. John's Wort).

          -  Medical history of ongoing clinically symptomatic severe psychiatric disorders.

          -  Parkinson's disease.

          -  Cushing disease or patients on supraphysiologic glucocorticoid therapy within 30 days
             prior to the anticipated first test day within the trial.

          -  Type 1 diabetes or untreated or poorly controlled Type 2 diabetes, as defined by
             HbA1c &gt; 8%.

          -  Body mass index (BMI) ≥ 40.0 kg/m2.

          -  Participation in a trial with any investigational drug within 30 days prior to trial
             entry.

          -  Vigorous physical exercise within 24 hours prior to each GHST within this trial.

          -  Known hypersensitivity to macimorelin or insulin, or any of the constituents of
             either preparation.

          -  Clinically significant cardiovascular or cerebrovascular disease.

          -  Prolonged ECG QT interval, defined as QTc &gt; 500 msec.

          -  Concomitant treatment with any drugs that might prolong QT/QTc.

          -  Elevation of laboratory parameters indicating hepatic or renal dysfunction or damage
             (ASAT, ALAT &gt; 2.5 x ULN; GGT, creatinine, or bilirubin &gt; 1.5x ULN).

          -  Medical history of seizure disorders.

          -  Known immunosuppression.

          -  Current active malignancy other than non-melanoma skin cancer.

          -  Breastfeeding or positive urine pregnancy test (for women of childbearing potential
             only).

          -  Women of childbearing age without contraception, such as hormonal contraception or
             use of condom and spermicides or use of diaphragm and spermicides or Intra Uterine
             Device (IUD).

          -  Lack of ability or willingness to give informed consent.

          -  Anticipated non-availability for trial visits/procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Garcia, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine, Houston, TX, U.S.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes and Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine-Endocrinology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center - Cherry Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Rudolfstiftung</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University &amp; General Hospital of Vienna, AKH,</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon HCL-GH Est</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHU Paris-Sud - Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU München</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Planck Institut</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen University Hospital</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Endokrinologie, Diabetes und Ernährungsmedizin der Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luca Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kliniczno-Badawcze</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phase I - MTZ Clinical Research Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wromedica</name>
      <address>
        <city>Wrocław</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia</name>
      <address>
        <city>Belgrad</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Conxo</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 9, 2017</lastchanged_date>
  <firstreceived_date>September 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult Growth Hormone Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Septo-Optic Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
